Henry Masur

60.4k total citations · 11 hit papers
375 papers, 33.5k citations indexed

About

Henry Masur is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Henry Masur has authored 375 papers receiving a total of 33.5k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Epidemiology, 165 papers in Infectious Diseases and 69 papers in Virology. Recurrent topics in Henry Masur's work include Pneumocystis jirovecii pneumonia detection and treatment (131 papers), HIV/AIDS drug development and treatment (80 papers) and HIV Research and Treatment (68 papers). Henry Masur is often cited by papers focused on Pneumocystis jirovecii pneumonia detection and treatment (131 papers), HIV/AIDS drug development and treatment (80 papers) and HIV Research and Treatment (68 papers). Henry Masur collaborates with scholars based in United States, Germany and Uganda. Henry Masur's co-authors include Joseph A. Kovacs, H. Clifford Lane, Naomi P. O’Grady, Anthony S. Fauci, Issam Raad, Mary Alexander, Stephen O. Heard, Adrienne G. Randolph, Leonard A. Mermel and Michele L. Pearson and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Henry Masur

366 papers receiving 31.5k citations

Hit Papers

Guidelines for the Preventi... 1981 2026 1996 2011 2011 2004 2004 1983 1981 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guidelines for the Prevention of Intravascular Catheter-related Infections
    2011 2.6k citations Henry Masur et al. Clinical Infectious Diseases profile →
  2. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
    2004 2.3k citations R. Phillip Dellinger, Jean Carlet et al. profile →
  3. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
    2004 2.0k citations R. Phillip Dellinger, Jean Carlet et al. Critical Care Medicine profile →
  4. Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency Syndrome
    1983 1.3k citations H. Clifford Lane, Henry Masur et al. profile →
  5. An Outbreak of Community-AcquiredPneumocystis cariniiPneumonia
    1981 1.0k citations Henry Masur et al. profile →
  6. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America
    2009 1000 citations Jonathan E. Kaplan, King K. Holmes et al. profile →
  7. Guidelines for the prevention of intravascular catheter-related infections
    2011 780 citations Henry Masur et al. profile →
  8. Guidelines for the Prevention of Intravascular Catheter–Related Infections
    2002 662 citations Henry Masur et al. profile →
  9. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    1999 639 citations Richard T. Davey, Julia A. Metcalf et al. profile →
  10. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi
    1988 550 citations Joseph A. Kovacs, Henry Masur et al. profile →
  11. Summary of Recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections
    2011 379 citations Henry Masur et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henry Masur United States 88 17.4k 10.4k 6.1k 5.1k 4.6k 375 33.5k
John G. Bartlett United States 91 20.5k 1.2× 16.2k 1.6× 2.5k 0.4× 1.7k 0.3× 1.2k 0.3× 404 45.8k
David L. Paterson Australia 106 19.2k 1.1× 15.2k 1.5× 1.3k 0.2× 1.4k 0.3× 813 0.2× 586 61.6k
Kathryn M. Edwards United States 91 21.2k 1.2× 10.5k 1.0× 721 0.1× 3.0k 0.6× 867 0.2× 557 31.2k
Trish M. Perl United States 68 5.2k 0.3× 8.4k 0.8× 1.0k 0.2× 612 0.1× 2.2k 0.5× 287 24.6k
Emilio Bouza Spain 77 15.9k 0.9× 15.8k 1.5× 500 0.1× 727 0.1× 2.8k 0.6× 862 29.3k
Larry J. Anderson United States 81 17.9k 1.0× 10.3k 1.0× 436 0.1× 3.2k 0.6× 921 0.2× 266 25.1k
Giuseppe Ippolito Italy 67 6.6k 0.4× 10.9k 1.0× 2.7k 0.4× 1.4k 0.3× 704 0.2× 533 18.4k
Robert A. Weinstein United States 78 7.3k 0.4× 9.4k 0.9× 544 0.1× 306 0.1× 2.7k 0.6× 349 27.9k
Nicola Principi Italy 63 8.8k 0.5× 3.9k 0.4× 793 0.1× 1.2k 0.2× 671 0.1× 591 16.5k
Thierry Calandra Switzerland 87 13.6k 0.8× 8.3k 0.8× 303 0.0× 12.8k 2.5× 384 0.1× 254 33.9k

Countries citing papers authored by Henry Masur

Since Specialization
Citations

This map shows the geographic impact of Henry Masur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Masur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Masur more than expected).

Fields of papers citing papers by Henry Masur

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Masur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Masur. The network helps show where Henry Masur may publish in the future.

Co-authorship network of co-authors of Henry Masur

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Masur. A scholar is included among the top collaborators of Henry Masur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Masur. Henry Masur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harfouch, Omar, Andrea Lisco, Ashley Davis, et al.. (2024). High Rates of High-risk HPV Anal Infection and Abnormal Cytology in a Cohort of Transgender People Assigned Male at Birth. Open Forum Infectious Diseases. 11(12). ofae662–ofae662. 2 indexed citations
2.
Kuriakose, Safia, Alice K. Pau, Eric S. Daar, et al.. (2021). Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of Internal Medicine. 174(8). 1151–1158. 13 indexed citations
3.
Townsend, Kerry, Eric G. Meissner, Sreetha Sidharthan, et al.. (2015). Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Research and Human Retroviruses. 32(5). 456–462. 28 indexed citations
4.
Shaffer, Ashton A., Jon Hubbard, Kerry Townsend, et al.. (2014). Short Communication: Serum-Based Assay Accurately Detects Single Nucleotide Polymorphisms of IL28B and SOCS3 in HIV/Hepatitis C Virus-Coinfected Subjects. AIDS Research and Human Retroviruses. 30(8). 792–795. 3 indexed citations
5.
Osinusi, Anu, Lisa Feldman Barrett, Kerry Townsend, et al.. (2014). Interleukin-23 Promotes Interferon-α Responsiveness in Hepatitis C Virus/HIV-Coinfected Patients. AIDS Research and Human Retroviruses. 30(8). 775–782. 6 indexed citations
6.
Funk, Emily K., Ashton A. Shaffer, Bhavana Shivakumar, et al.. (2013). Short Communication: Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses. 29(9). 1190–1194. 7 indexed citations
7.
Meissner, Eric G., Dimitra Bon, Ludmila Prokunina‐Olsson, et al.. (2013). IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. The Journal of Infectious Diseases. 209(11). 1700–1704. 76 indexed citations
8.
Barrett, Lisa Feldman, Anu Osinusi, Anita Kohli, et al.. (2013). 1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY. Journal of Hepatology. 58. S1–S1. 13 indexed citations
9.
Naggie, Susanna, Anu Osinusi, Antonios Katsounas, et al.. (2012). Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response. Hepatology. 56(2). 444–454. 55 indexed citations
10.
Sherman, Amy C, Nirupama Trehanpati, Marybeth Daucher, et al.. (2012). Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir. AIDS Research and Human Retroviruses. 29(4). 665–672. 27 indexed citations
11.
Tavel, Jorge A., Chiung‐Yu Huang, Julia A. Metcalf, et al.. (2010). Interferon-α Produces Significant Decreases in HIV Load. Journal of Interferon & Cytokine Research. 30(7). 461–464. 33 indexed citations
12.
Kottilil, Shyam, Richard A. Lempicki, Jun Yang, et al.. (2006). Hepatic Histologic Response (HR) to Combination Therapy among HCV/HIV-Coinfected Individuals: Interferon Induces HR Independent of Sustained Virologic Response (SVR). AIDS Research and Human Retroviruses. 22(11). 1091–1098. 4 indexed citations
13.
Dellinger, R. Phillip, Jean Carlet, Henry Masur, et al.. (2004). Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical Care Medicine. 32(3). 858–873. 1972 indexed citations breakdown →
14.
Wright, Mary E., Daniel L. Suzman, Karl G. Csaky, et al.. (2003). Extensive Retinal Neovascularization as a Late Finding in Human Immunodeficiency Virus–Infected Patients with Immune Recovery Uveitis. Clinical Infectious Diseases. 36(8). 1063–1066. 18 indexed citations
15.
Kovacs, Joseph A., Susan Vogel, Randy Stevens, et al.. (2001). Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. European Journal of Immunology. 31(5). 1351–1360. 48 indexed citations
16.
Kovacs, Joseph A., Hiromi Imamichi, Susan Vogel, et al.. (2000). Effects of Intermittent Interleukin‐2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi‐Species Expression. The Journal of Infectious Diseases. 182(4). 1063–1069. 25 indexed citations
17.
Masur, Henry, King K. Holmes, & Jonathan E. Kaplan. (2000). Introduction to the 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 30(s1). S1–S4. 36 indexed citations
18.
Zunich, Kathryn M., H. Clifford Lane, Richard T. Davey, et al.. (1992). Phase I/II Studies of the Toxicity and Immunogenicity of Recombinant gp160 and p24 Vaccines in HIV-Infected Individuals. AIDS Research and Human Retroviruses. 8(8). 1335–1335. 6 indexed citations
19.
20.
Rogers, Paul L., Robert Walker, H. Clifford Lane, et al.. (1988). Disseminated mycobacterium haemophilum infection in two patients with the acquired immunodeficiency syndrome. The American Journal of Medicine. 84(3). 640–642. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John G. Bartlett Breakdown of academic impact, for papers by David L. Paterson Breakdown of academic impact, for papers by Kathryn M. Edwards Breakdown of academic impact, for papers by Trish M. Perl Breakdown of academic impact, for papers by Emilio Bouza Breakdown of academic impact, for papers by Larry J. Anderson Breakdown of academic impact, for papers by Giuseppe Ippolito Breakdown of academic impact, for papers by Robert A. Weinstein Breakdown of academic impact, for papers by Nicola Principi Breakdown of academic impact, for papers by Thierry Calandra
Rankless by CCL
2026